Index

Note: Page numbers of article titles are in **boldface** type.

**A**

Acamprosate, for alcohol use disorder, 830–832
Active surveillance, for prostate cancer, 797–798
Agency for Health Research and Quality, lung cancer screening guidelines of, 776
Alcohol, unhealthy use of. See Unhealthy alcohol use.
Alcohol Use Disorders Identification Test (AUDIT), 826–828
Alcoholics Anonymous, 829–830
5-Alpha-reductase inhibitors, for prostate cancer prevention, 789–790
Ambulatory blood pressure monitoring, 704
American Academy of Family Physicians, lung cancer screening guidelines of, 775–776
American Association of Thoracic Surgery, lung cancer screening guidelines of, 773–774
American Cancer Society
  - lung cancer screening guidelines of, 773–774
  - prostate cancer screening guidelines of, 795–796
American College of Chest Physicians, lung cancer screening guidelines of, 773–774, 779–780
American College of Physicians, prostate cancer screening guidelines of, 795–796
American College of Radiology, 735–736
American Society of Clinical Oncology, prostate cancer screening guidelines of, 795–796
American Urological Association, prostate cancer screening guidelines of, 795–796
Ankle-brachial index, 680
Antidepressants, for depression, 808–818
Antihypertensive therapy, 703, 707–709
Antineoplastic effects, of aspirin, 717–718
Antiplatelet activity, of aspirin, 715–721
ARIC (Atherosclerosis Risk Development in Young Adults) study, 676
Aspirin, preventive function of, **713–724**, 763
  - modeling of benefits and harms, 718–719
  - recommendations for, 713–717
  - uncertainty about, 719–721
Atherosclerosis, 675
  - prevention of, statins for, **689–699**
  - subclinical, 677, 680–681
Atherosclerosis Risk Development in Young Adults (ARIC) study, 676
AUDIT (Alcohol Use Disorders Identification Test), 826–828
Automated blood pressure monitoring, 704

**B**

Balancing measures, in depression treatment, 818
Biopsy, prostate, 793, 797
**Bleeding, aspirin-related**, 717–718

**Blood pressure**
- high, 701–712
- measurement of, 703–705

**BRCAPRO calculator**, 737

**Breast cancer, 725–741**
- risk factors for, 727–728
- screening for
  - breast density and, 727–734
  - protocols for, 727
  - shared decision-making in, 736–737

**Breast Cancer Surveillance Consortium**, 737

**Breast Imaging Reporting and Data system**, 727

**C**

**CAGE questionnaire**, 828

**Cancer**
- breast, 725–741
- cervical, 743–753
- colorectal, 713–724, 755–767

**Cancer Intervention and Surveillance Modeling Network (CISNET)**, 727

**CARDIA (Coronary Artery Risk Development in Young Adults) Study**, 676

**Cardiovascular disease**
- aspirin preventive function for, 713–724
- risk assessment of, 673–688
  - benefits of, 674–675
  - future of, 681–683
  - history of, 674–675
  - multivariable equations for, 675–676
  - novel risk factors for, 677–681
  - traditional risk factors in, 675
- statins for, 689–699

**Center for Epidemiologic Studies Depression Scale**, 810

**Cervical cancer, 743–753**
- epidemiology of, 744
- progression of, 744
- screening for, 746–749
- vaccines for, 744–745

**Chemoprevention, for prostate cancer**, 789–790

**Chemotherapy, for lung cancer**, 770

**Chest radiography, for lung cancer**, 771

**Cholesterol, measurement of**, 681

**CISNET (Cancer Intervention and Surveillance Modeling Network)**, 727

**Cognitive behavioral therapy**
- for alcohol use disorder, 829–830
- for depression, 814

**Colonoscopy, for cancer screening**, 757–763

**Colorectal cancer, 755–767**
- aspirin preventive function for, 713–724
- epidemiology of, 755–756
screening for
  guidelines for, 758, 761–763
  rationale for, 756
  risk factors for, 756–757
  tests for, 757–761
Colposcopy, 745–746
COMBINE (Combined Pharmacotherapies and Behavioral Interventions) Study, 833
Computed tomography, low-dose, for lung cancer, 769–779
Computed tomography colonography, for cancer screening, 757–762
Contrast-enhanced spectral mammography, 732, 734
Coronary artery calcium, 680
Coronary Artery Risk Development in Young Adults (CARDIA) Study, 676
Counseling, for risky drinking, 829
C-reactive protein, 681
Cytology, for cervical cancer screening, 747–749

D

Danish Lung Cancer Screening Trial, 772
Dartmouth Hitchcock Medical Center, 800–801
Dartmouth Institute, lung cancer screening guidelines of, 776
Department of Veterans Affairs, lung cancer screening guidelines of, 776
Depression, 807–821
  epidemiology of, 807–808
  screening for
    benefits of, 810
    cost-effectiveness of, 817, 819
    frequency of, 810
    harms of, 810–811
    implementation of, 811–813
    instruments for, 809–810
    measuring improvement, 815, 817
    populations for, 808
    treatment of, 813–816
Diet, for cancer prevention, 763
Digital Mammographic Imaging Screening Trial (DMIST), 729–730
Digital rectal examination, 791–792
Disulfiram, for alcohol use disorder, 830–832
DMIST (Digital Mammographic Imaging Screening Trial), 729–730
DNA test, for colorectal cancer detection, 757–762
Drinking, risky. See Unhealthy alcohol use.
Dual-energy contrast-enhanced spectral mammography, 732–734
Dutasteride, for prostate cancer prevention, 789–790
Dutch-Belgian Randomized Lung Cancer Screening trial, 771–772

E

Edinburgh Postnatal Depression Scale, 810
European Randomized Study of Screening for Prostate Cancer Screening Trial, 792–793, 797
Index

F
Fecal occult blood test, 756–762
Finasteride, for prostate cancer prevention, 789–790
Flexible sigmoidoscopy, for colorectal cancer, 757–762
Framingham Heart Study, 674–676

G
Genetic factors
in cardiovascular disease, 681
in colorectal cancer, 756–757

H
Home blood pressurize monitoring, 704–705
Human immunodeficiency virus infection, statin therapy and, 696
Human papillomavirus, in cervical cancer, 743–751
Hypertension, 701–712
blood pressure measurement for, 703–705
epidemiology of, 702–703
importance of, 701–702
screening for, 705–707
treatment of, 682–683, 703, 707–709

I
Immunochemical test, for colorectal cancer, 756–762
Informed Medical Decision Foundation, 800–801

J
JUPITER trial, 692

K
Kidney dysfunction, statin therapy and, 695–696

L
Lifestyle changes
for cancer prevention, 763
for hypertension, 707
for prostate cancer prevention, 789
Lipoprotein-associated phospholipase A2, 681
Lung cancer, 769–785
clinical presentation of, 770
control strategies for, 770–773
pathology of, 770
screening for
guidelines for, 773–775
implementing programs, 779–781
practical aspects of, 775–779
shared decision-making for, 775
staging of, 770
survival in, 770
treatment of, 770

Lung Cancer Alliance Screening Centers of Excellence database, 781
Lung Imaging Reporting and Data System, 776–778

M
Magnetic resonance imaging, for breast screening, 732–734
Mammography, for screening, 727–737
Masking effect, of dense breasts, 729–730
Massachusetts General Hospital, prostate cancer screening decision aids of, 799–801
Memorial Sloan Kettering Cancer Center, lung cancer screening guidelines of, 776
MILD (Multicentric Italian Lung Detection trial), 772
Molecular breast imaging, 732, 734
Motivational interviewing, for risky drinking, 829
Multicentric Italian Lung Detection trial (MILD), 772
Myalgia, in statin therapy, 695
Myocardial infarction, prevention of, aspirin for, 715–716

N
Nalmefene, for alcohol use disorder, 831
Naltrexone, for alcohol use disorder, 830–832
National Cancer Institute, lung cancer screening guidelines of, 776
National Cancer Institute Breast Cancer Risk Assessment Too, 737
National Cholesterol Education Program, 674
National Comprehensive Cancer Network
breast cancer screening guidelines of, 735
lung cancer screening guidelines of, 773–774
National Coverage Determination, for lung cancer screening, 773
National Lung Screening Trial, 769–782
Nederlands Leuvent Longkanker Screening Onderzoek (NELSON), 772–773
Nutrition, for prostate cancer prevention, 789

O
Older adults, depression screening in, 808–810
Outcome measures, in depression treatment, 818

P
Patient Health Questionnaire, 808–818
PIVOT (Prostate Cancer Intervention Versus Observation Trial), 793–794
Polyps, in colon, 756
Pooled Cohorts atherosclerotic cardiovascular disease Risk Equations, 676–679
Postpartum women, depression screening in, 808–810
Pregnant women, depression screening in, 808–810
Preventive services
aspirin for, 713–724
for breast cancer, 725–741
for cardiovascular disease
   blood pressure control, 701–712
   risk assessment, 673–688
   statins for, 689–699
for cervical cancer, 743–753
for colorectal cancer, 755–767
for depression, 807–821
for lung cancer, 769–785
for prostate cancer, 787–806
for unhealthy alcohol use, 823–837
Problem-solving therapy, 814
Process measures, in depression treatment, 818
PROJECT MATCH, for alcohol use disorder, 830
Prostate cancer, 787–806
   incidence of, 787–788
   mortality in, 787–788
   primary prevention of, 789–790
   risk factors for, 788–789
   screening for
      digital rectal examination for, 791–792
      guidelines for, 795–796
      legal issues in, 801
      new strategies for, 797–798
      prostate-specific antigen test for, 792–795
      shared decision-making for, 798–801
   time trends in, 788
Prostate Cancer Intervention Versus Observation Trial (PIVOT), 793–794
Prostate Cancer Prevention Trial, 790–791
Prostate, Lung, Colorectal and Ovarian Screening Trial, 792
Prostate-specific antigen test, 788–795
ProtecT Treatment Trial, 793–795
Psychotherapy, 811–819

R
Radiation therapy, for lung cancer, 770
Resection, for lung cancer, 770
Reynolds risk functions, 676, 678
Rhabdomyolysis, in statin therapy, 695
Risk prediction, of cardiovascular disease, 673–688
Risky drinking. See Unhealthy alcohol use.

S
Shared decision-making
   for breast cancer screening, 736–737
   for lung cancer screening, 775
   for prostate cancer screening, 798–800
Smoking cessation, for lung cancer prevention, 770–771, 778
Sphygmomanometer, 703–704
SPRINT (Systolic Blood Pressure Treatment Trial), 682–683, 707–709
Statins, 689–699
  clinical management of, 693–695
  cost-effectiveness of, 692–693
  efficacy of, 690–691
  recommendations for, 692
  safety of, 691–692
  uncertainty about, 695–696
Stool DNA test, for colorectal cancer detection, 757–762
Stroke, prevention of, aspirin for, 716
Surveillance, Epidemiology and End Results Program, 770
Sys-Eur Trial, 705–707
Systolic Blood Pressure Treatment Trial (SPRINT), 682–683, 707–709
T
Tomosynthesis, for mammography, 730–732
Topiramate, for alcohol use disorder, 831
Tumor Node Metastasis system, 770
Tyres-Cuzik calculator, 737
U
Ultrasonography, for breast screening, 732–733
Unhealthy alcohol use, 823–837
  interventions for, 829–832
  prevalence of, 824
  screening for, 826–829, 832–833
United States Preventive Services Task Force guidelines
  for alcohol consumption, 825
  for breast cancer screening, 733, 735
  for depression screening, 818
  for lung cancer screening, 773–774
  for prostate cancer screening, 795–796
University of Michigan, lung cancer screening guidelines of, 776